Dae Young Zang

16PUBLICATIONS
55CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Disease surveillancePharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jul 30, 2024
FDA regulatory considerations for oncology drug development.

Hanlim Moon, Dae Young Zang, Min-Hee Ryu

|Jul 12, 2024
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.

Yoon-Koo Kang, Hyung-Don Kim, Jeong Hwan Yook

|Oct 26, 2023
Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study.

Choong-Kun Lee, Hyo Song Kim, Minkyu Jung

|Jun 26, 2023
Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric or Gastroesophageal Junction Cancer.

Chang Gon Kim, Minkyu Jung, Hyo Song Kim

|Nov 07, 2022
Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study Group.

Hye Sook Han, Kyoung Eun Lee, Young Ju Suh

|Oct 12, 2022
A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer.

Choong-Kun Lee, Sun Young Rha, Hyo Song Kim

Pageof 3

Frequent Collaborators

4 joint publications

Sun Young Rha

3 joint publications

Dong-Hoe Koo

3 joint publications

Choong-Kun Lee

2 joint publications

Chung Mo Nam